Astrazeneca (AZN) Work In Process (2016 - 2025)

Astrazeneca has reported Work In Process over the past 11 years, most recently at $2.8 billion for Q4 2025.

For Q4 2025, Work In Process rose 21.69% year-over-year to $2.8 billion; the TTM value through Dec 2025 reached $2.8 billion, up 21.69%, while the annual FY2025 figure was $2.8 billion, 21.69% up from the prior year.
Work In Process for Q4 2025 was $2.8 billion at Astrazeneca, up from $2.3 billion in the prior quarter.
Over five years, Work In Process peaked at $5.2 billion in Q4 2021 and troughed at $1.9 billion in Q4 2022.
A 5-year average of $2.9 billion and a median of $2.3 billion in 2023 define the central range for Work In Process.
Biggest five-year swings in Work In Process: skyrocketed 291.89% in 2021 and later crashed 64.26% in 2022.
Year by year, Work In Process stood at $5.2 billion in 2021, then crashed by 64.26% to $1.9 billion in 2022, then grew by 24.73% to $2.3 billion in 2023, then dropped by 1.85% to $2.3 billion in 2024, then grew by 21.69% to $2.8 billion in 2025.
Business Quant data shows Work In Process for AZN at $2.8 billion in Q4 2025, $2.3 billion in Q4 2024, and $2.3 billion in Q4 2023.

Peer Comparison